Daiwa: Z.AI (02513) risk-reward has improved significantly; reiterates "Buy" rating
The company's stock valuation has reset to approximately 14x 2026E EV/ARR, and the risk-reward has improved significantly.
Daiwa released a research report stating that Z.AI (02513) has raised its 2026 expected annual recurring revenue target to US$3 billion, and reiterated its "Buy" rating.
The bank believes that industry dynamics are changing rapidly, including falling token prices and rising scrutiny of the long-term economic benefits of models, requiring a more prudent assessment of returns; however, with the stock's valuation reset to approximately 14 times 2026 expected enterprise value/ARR, the risk-reward has improved significantly.
The bank mentioned that Z.AI's approximately US$5 billion financing will be used to expand computing power, removing near-term revenue growth constraints, and that there are no plans for further equity financing before a potential A-share listing.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





